PURETECH HEALTH PLC financials
Also U.S.-listed. PURETECH HEALTH PLC is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: PRTCY — PURETECH HEALTH PLC
PURETECH HEALTH PLC
Country: GB Reporting currency: USD Latest annual report: 2025-12-31
LEI:
213800LVPDNO2Z9T9I39 Financial statements
(USD, as reported — unscaled; 107 line items across 3 annual periods)
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Revenue | $4.7M | $4.8M | $3.3M |
| Operating profit (EBIT) | -$98.5M | -$136.1M | -$146.2M |
| Net finance income / (cost) | -$32.7M | $4.8M | $5.1M |
| Finance costs | $1.9M | $1.7M | $3.4M |
| Profit before tax | -$110.9M | $23.8M | -$36.1M |
| Income tax expense | -$842.0K | -$4.0M | $30.5M |
| Profit for the year | -$110.1M | $27.8M | -$66.6M |
| — attributable to owners | -$109.7M | $53.5M | -$65.7M |
| — attributable to NCI | -$345.0K | -$25.7M | -$931.0K |
| Total comprehensive income | -$110.1M | $27.8M | -$66.5M |
| Per share | |||
| Basic EPS | $-0.46 | $0.21 | $-0.24 |
| Diluted EPS | $-0.46 | $0.21 | $-0.24 |
| Free cash flow / share | $-0.36 | $-1.02 | $-0.38 |
| Cash flow statement | |||
| Net cash from operating activities | -$85.1M | -$134.4M | -$105.9M |
| Net cash from investing activities | $63.3M | $240.9M | $69.0M |
| Purchase of PP&E (capex) | $6.0K | $11.0K | $70.0K |
| Purchase of intangibles | $0 | $0 | $175.0K |
| Net cash from financing activities | -$6.3M | -$17.0M | $78.1M |
| Lease liability payments | $3.6M | $3.4M | $3.3M |
| Net change in cash | -$28.2M | $89.6M | $41.2M |
| Balance sheet | |||
| Total assets | $534.7M | $602.6M | — |
| Non-current assets | $229.7M | $216.4M | — |
| Property, plant & equipment | $5.2M | $7.1M | — |
| Right-of-use assets | $6.3M | $8.1M | — |
| Current assets | $305.0M | $386.3M | — |
| Trade & other receivables | $1.8M | $1.5M | — |
| Cash & equivalents | $252.5M | $280.6M | $191.1M |
| Total equity | $305.7M | $407.9M | $458.2M |
| — attributable to owners | $312.1M | $414.7M | — |
| Non-controlling interests | -$6.4M | -$6.8M | — |
| Non-current liabilities | $182.7M | $153.3M | — |
| Lease liabilities (non-current) | $11.1M | $14.7M | — |
| Current liabilities | $46.3M | $41.4M | — |
| Lease liabilities (current) | $3.6M | $3.6M | — |
| Trade & other payables | $23.2M | $27.0M | — |
| Derived metrics | |||
| Free cash flow | -$85.1M | -$134.4M | -$106.0M |
| Operating margin | -2114.8% | -2818.9% | -4390.4% |
| Net margin | -2362.8% | 575.4% | -2000.8% |
| Return on equity | -36.0% | 6.8% | -14.5% |
| Cash conversion ratio | 0.77× | -4.84× | 1.59× |
| Capex coverage | -14188.50× | -12215.36× | -1513.10× |
| Other reported items | |||
| Adjustments For Decrease Increase In Other Current Assets | -$1.9M | -$1.3M | $2.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -$236.0K | $629.0K | $9.8M |
| Adjustments For Depreciation and Amortisation Expense | $3.3M | $3.6M | $4.9M |
| Adjustments For Fair Value Gains Losses | -$38.5M | $2.4M | -$77.9M |
| Adjustments For Finance Income Cost | -$32.7M | $4.8M | $5.1M |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | $0 | $151.8M | $61.8M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | $93.0K | -$14.0K | -$318.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $112.0K | $226.0K | $1.3M |
| Adjustments For Income Tax Expense | -$842.0K | -$4.0M | $30.5M |
| Adjustments For Increase Decrease In Trade Account Payable | -$1.0M | -$9.7M | $3.8M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -$375.0K | -$151.0K | $265.0K |
| Adjustments For Sharebased Payments | $8.2M | $22.9M | $4.4M |
| Comprehensive Income Attributable To Noncontrolling Interests | -$345.0K | -$25.7M | -$931.0K |
| Comprehensive Income Attributable To Owners of Parent | -$109.7M | $53.5M | -$65.6M |
| Current Prepaid Expenses | $6.6M | $4.4M | — |
| Current Receivables Due From Associates | $11.4M | $11.4M | — |
| Current Tax Assets Current | $6.4M | $0 | — |
| Current Tax Liabilities Current | $1.2M | $75.0K | — |
| Equity and Liabilities | $534.7M | $602.6M | — |
| Finance Income | $13.0M | $22.7M | $16.0M |
| Gains Losses On Disposals of Investments | $375.0K | $151.0K | -$122.0K |
| Gains Losses On Exchange Differences On Translation Before Tax | $0 | $0 | $92.0K |
| Gains Losses Recognised In Profit Or Loss Fair Value Measurement Assets | $38.5M | -$2.4M | $77.9M |
| Gains Losses Recognised In Profit Or Loss Fair Value Measurement Liabilities | $0 | -$8.1M | $2.6M |
| Gains Losses Recognised When Control In Subsidiary Is Lost | $0 | $151.8M | $61.8M |
| General and Administrative Expense | $46.6M | $71.5M | $53.3M |
| Income Taxes Paid Refund Classified As Operating Activities | $5.5M | $37.9M | $150.0K |
| Increase Decrease Through Change In Equity of Subsidiaries | — | $7.4M | -$9.1M |
| Increase Decrease Through Exercise of Options | $106.0K | $895.0K | $1.2M |
| Increase Decrease Through Sharebased Payment Transactions | $7.1M | $21.9M | $3.6M |
| Increase Decrease Through Transfers and Other Changes Equity | $23.0K | -$12.0K | -$6.0K |
| Intangible Assets Other Than Goodwill | $601.0K | $601.0K | — |
| Interest Paid Classified As Operating Activities | $4.5M | $1.3M | $1.7M |
| Interest Received Classified As Operating Activities | $13.6M | $23.5M | $14.5M |
| Investments In Associates | $0 | $2.4M | — |
| Issued Capital | $4.9M | $4.9M | — |
| Liabilities | $229.0M | $194.7M | — |
| Merger Reserve | $138.5M | $138.5M | — |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | $217.4M | $191.4M | — |
| Noncurrent Receivables Due From Associates | $0 | $6.3M | — |
| Notes and Debentures Issued | $4.9M | $4.1M | — |
| Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities | $2.8M | $298.1M | $33.3M |
| Other Comprehensive Income | $0 | $0 | $92.0K |
| Other Gains Losses | $1.3M | $961.0K | -$908.0K |
| Other Inflows Outflows of Cash Classified As Financing Activities | $0 | $0 | -$23.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | $50.0K | $0 | $0 |
| Other Inflows Outflows of Cash Classified As Operating Activities | $0 | $92.0K | $1.4M |
| Other Noncurrent Assets | $165.0K | $475.0K | — |
| Other Operating Income Expense | $36.6M | $163.7M | $111.1M |
| Other Reserves | -$3.4M | -$4.7M | — |
| Proceeds From Exercise of Options | $106.0K | $895.0K | $1.2M |
| Proceeds From Issue of Preference Shares | $0 | $68.1M | $0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | $269.0K | $255.0K | $865.0K |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | $145.3M | $357.4M | $244.6M |
| Purchase of Financial Instruments Classified As Investing Activities | $84.0M | $308.9M | $178.9M |
| Purchase of Interests In Associates | $888.0K | $14.4M | $0 |
| Purchase of Treasury Shares | — | $4.8M | $19.6M |
| Research and Development Expense | $56.6M | $69.5M | $96.2M |
| Reserve of Exchange Differences On Translation | $182.0K | $182.0K | — |
| Restricted Cash and Cash Equivalents | $1.6M | $1.6M | — |
| Retained Earnings | -$77.2M | $32.5M | — |
| Revenue From Contracts With Customers | $4.7M | $4.3M | $750.0K |
| Revenue From Government Grants | $0 | $513.0K | $2.6M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -$17.9M | -$8.8M | -$6.1M |
| Share Premium | $290.3M | $290.3M | — |
| Treasury Shares | $41.2M | $46.9M | — |
Methodology
Every line item above is a fact tagged in PURETECH HEALTH PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.